Revenue growth of 39% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data
Raises 2025 revenue guidance to $965 to $970 million, representing year-over-year growth of 31%
https://finance.yahoo.com/news/guardant-health-reports-third-quarter-200500592.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.